News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis (NVS): New Study Finds Coartem (Artemether-Lumefantrine) Is The Most Effective Malaria Treatment In Areas Of High Resistance To Conventional Anti-Malarials


10/19/2005 5:10:53 PM

BASEL, Switzerland, April 26, 2005 (PRIMEZONE) -- A new study published in The Lancet suggests that the combination of artemether and lumefantrine, available from Novartis (NYSE:NVS) under the brand name Coartem(R) , is the most effective available treatment for malaria in children in areas of Africa where resistance to conventional anti-malarial drugs is high. Developed and produced by Novartis and its Chinese partners, Coartem is currently the only fixed-dose artemisinin-based combination therapy pre-qualified by the World Health Organization (WHO) for procurement by United Nations agencies.

Read at Prime Zone

comments powered by Disqus
   
Malaria

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES